Sumitomo Pharma America Inc.

Clinical research in myelofibrosis centers on oral targeted therapy development, with attention to disease control in intermediate and high-risk settings. The sponsor’s work in this area includes evaluation of treatment approaches intended to address marrow fibrosis and related myeloproliferative neoplasm features.

• Targeted therapy for myelofibrosis
• Myeloproliferative neoplasm management
• Intermediate and high-risk disease

Interest extends to combination strategies and symptom-relevant disease modification in patients with persistent hematologic burden.